Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes: a Phase 2 Double Blinded Placebo Controlled Clinical Trial (TIRTLE2)
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This study will examine the effects of Tirzepatide (TZP), a glucagon-like peptide 1 (GLP1) - gastric inhibitory peptide (GIP) co-agonist, on metabolism in type 1 diabetes (T1D). Research participants with T1D will undergo measures of insulin sensitivity, and hormone levels post-meal, post-hypoglycemia and during the overnight period. These measures will be performed prior to, and after 6 weeks of treatment with TZP or placebo.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• age 18-65 years
• BMI ≥ 27 kg/m2
• HbA1c ≤ 9.0%
• insulin delivery using an automated insulin delivery system
• at least 2 years since diagnosis of type 1 diabetes
Locations
Other Locations
Australia
Victor Chang Cardiac Research Institute
RECRUITING
Sydney
Contact Information
Primary
Jennifer R Snaith, MD PHD
j.snaith@victorchang.edu.au
+61 2 9295 8600
Backup
Jerry R Greenfield, MD PHD
j.greenfield@victorchang.edu.au
Time Frame
Start Date: 2026-07-07
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 44
Treatments
Experimental: Tirzepatide 2.5mg weekly
Administered subcutaneously.
Placebo_comparator: Placebo
Administered subcutaneously.
Related Therapeutic Areas
Sponsors
Leads: Victor Chang Cardiac Research Institute